FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

OMB APPROVAL									
OMB Number	3235-02								

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Glucksmann Alexandra						2. Issuer Name and Ticker or Trading Symbol Editas Medicine, Inc. [EDIT]								eck all appl Direct	ationship of Reportin k all applicable) Director Officer (give title		son(s) to Iss 10% Ov Other (s	vner
(Last) (First) (Middle) C/O EDITAS MEDICINE, INC. 11 HURLEY ST.					3. Date of Earliest Transaction (Month/Day/Year) 02/15/2017									below) below) Chief Operating Officer				
(Street) CAMBRIDGE MA 02141 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(5		,	on-Deriv	/ative	e Sec	uriti	ies Ac	quirec	l, Di	sposed c	of, or Be	neficial	ly Owne	d			
		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			Benefic Owned	ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Report Transa (Instr. :	ed ction(s) 3 and 4)			(Instr. 4)
Common Stock			02/15/	2017	2017			M ⁽¹⁾		6,000	A	\$0.65	12	3,788		D		
Common Stock 02.				02/15/	2017	2017			S ⁽¹⁾		5,000	D	\$20	11	8,788		D	
Common Stock 02/15/2			2017	017			S ⁽¹⁾		1,000	D	\$23.48	44 11	117,788		D			
		7	able II								posed of converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution th/Day/Year) Execution th/Day/Year)					6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactir (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to	\$0.65	02/15/2017			M ⁽¹⁾			6,000	(2)		04/15/2025	Common Stock	6,000	\$0	31,46	1	D	

Explanation of Responses:

- 1. The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016.
- 2. This option was granted on April 16, 2015 and is scheduled to vest over four years with 25% of the shares having vested on March 9, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through March 9, 2019.

/s/ Alexandra Glucksmann 02/16/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.